Survivin and SIRT1: can be two prognostic factors in chronic myeloid leukemia?

In this study, we measured the expression of SVV and SIRT1 in 18 patients with typical Ph-positive chronic myeloid leukemia in chronic phases of the disease as well as in 18 matched healthy donors. SVV, SIRT1, and BCR/ABL expression were determined by quantitative-real-time polymerase chain reaction (Q-RT-PCR). HPRT was used as a reference gene to calculate SVV/HPRT and SIRT1/HPRT ratio, and ABL was used as an internal control for BCR/ABL expression. SVV was between 0.00 and 2.39-fold (median 0.204) and SIRT1 was between 0.00 and 33.32-fold (median 0.186). In our study, both SVV and SIRT1 were lower in patients than in the controls (p = 0.001 and 0.001, respectively). Although the expression of SVV and SIRT1 was decreased in patients with chronic phase (0.043 and 0.043-fold, respectively), a potent expression upregulation of both genes was found in K562, Jurkat, and U937 cell lines. Despite lower expression of both SVV and SIRT1 at chronic phase, a significant correlation was found between SVV expression levels and minor Hb concentration (
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research

Related Links:

Conclusion.Planned pregnancy might be pragmatic in female patients with CML on TKIs. Achieving deep molecular response and, importantly, MMR duration ≥3.5 years were significantly associated with maintaining MMR during pregnancy.Implications for Practice.Female patients with chronic myeloid leukemia on tyrosine kinase inhibitors (TKIs) wishing to conceive are currently advised to discontinue TKIs before conception. However, the ideal degree and duration of response before stopping TKI, in addition to whether there will be any adverse effect caused by a short exposure of TKI, is unknown. Data of 17 female patients, who a...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Leukemias, Hematologic Malignancies Source Type: research
In this study, we show that different TKIs used for treatment of Chronic Myeloid Leukemia have opposing effects on platelet function, with large inter ‐individual differences. Thus, in patients with high risk for hemostatic or thrombotic complications, we suggest that treatment with TKIs should be individualized to minimize risks associated with long‐term treatment. AbstractSince their introduction, tyrosine kinase inhibitors (TKIs, eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib) have revolutionized the treatment of chronic myeloid leukemia (CML). However, long ‐term treatment with TKIs is associated with s...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31714657 [PubMed - as supplied by publisher]
Source: Biomed Res - Category: Research Authors: Tags: J Biomed Mater Res A Source Type: research
Abstract The BCR-ABL1 fusion gene is the driver mutation of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Its expression level in CML patients is monitored by a real-time quantitative polymerase chain reaction defined by the International Scale (qPCRIS). BCR-ABL1 has also been found in asymptomatic normal individuals using a non-qPCRIS method. In the present study, we examined the prevalence of BCR-ABL1 in a normal population in southern Sarawak by performing qPCRIS for BCR-ABL1 with ABL1 as an internal control on total white blood cells, using an unbiased sampling method. While 146 of 190 (76.8...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
Nilotinib, a tyrosine kinase inhibitor, used for the treatment of chronic myeloid leukemia (CML), is known to produce atherosclerotic complications such as coronary artery disease, peripheral artery disease [1] and intracranial arterial stenosis/occlusion (ICASO) [2,3]. Middle cerebral artery (MCA) is the most common site involved in ICASO in CML patients treated with nilotinib [2]. It has been remained unknown what factors influence the development of ICASO in patients treated with nilotinib. Because reported patients with ICASO were rare, there is a possibility that some specific factors such as genetic mutations are ass...
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
Publication date: Available online 7 November 2019Source: Journal of Chemical NeuroanatomyAuthor(s): Henrique J.C.B. Gouveia, Raul Manhães-de-Castro, Bárbara J.R. Costa-de-Santana, Carolina R. Mendonça, Glayciele Leandro de Albuquerque, Diego Bulcão Visco, Diego Cabral Lacerda, Ana Elisa ToscanoAbstractBusulfan is a bifunctional alkylating agent used for myeloablative conditioning and in the treatment of chronic myeloid leukemia due to its ability to cause DNA damage. However, in rodent experiments, busulfan presented a potential teratogenic and cytotoxic effect. Studies have evaluated the effec...
Source: Journal of Chemical Neuroanatomy - Category: Neuroscience Source Type: research
We report a novel case in which hydroxyurea hyperpigmentation is associated with iron deposition.
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
UCLA legend and NBA Hall of Famer Kareem Abdul-Jabbar is teaming up with UCLA Health for a wide variety of new health and wellness initiatives designed to improve health and prevent disease.The partnership will be announced at the 2019 Leukemia and Lymphoma Society ’s Los Angeles Light the Night Walk, an event for which UCLA Health is the presenting sponsor.  The Los Angeles Laker superstar and UCLA Bruin basketball player is a survivor of chronic myeloid leukemia, or CML, which is a form of blood cancer. To honor his survivorship, Abdul-Jabbar has served as an ambassador and UCLA Health fundraising team ca...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
In this study, we found that miR328 significantly and strikingly decreased among other miRNA candidates during the induction of imatinib resistance. Overexpression of miR328 sensitized resistant cells to imatinib via post-transcriptionally decreasing ABCG2 expression, while miR328 knockdown conferred imatinib resistance in parental K562 cells. Moreover, miR328 was found selectively degraded in the lysosomes of K562R cells, as inhibition of lysosome with chloroquine restored miR328 expression and increased sensitivity to imatinib. Moreover, delivery of alkalized exosomes increased endogenous miR328 expression. Compared with...
Source: Applied Microbiology and Biotechnology - Category: Microbiology Authors: Tags: Appl Microbiol Biotechnol Source Type: research
AbstractPurposeIn chronic myeloid leukaemia, tyrosine kinase inhibitor treatment is traditionally given continuously for life. However, these drugs produce excellent responses for many patients, and this is accompanied by survival that is close to normal. This has prompted studies of whether it is possible to stop treatment, thus achieving a treatment-free remission (TFR).Recent FindingsMost TFR studies have focussed on abrupt cessation in patients with long-standing deep remissions, but recent data suggest that more gradual treatment de-escalation may improve TFR success, and that it may be possible to extend TFR attempts...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Hematology | Leukemia | Pathology | Study